Allurion Technologies announced clinical results from two new studies on the Elipse Gastric Balloon recently during ObesityWeek 2020 the company reports in a media release.

The Allurion Program features the Elipse Balloon, a procedureless weight loss device. The balloon is designed to remain in the stomach for 4 months and is paired with a Bluetooth-connected scale and Allurion smartphone app and a supervised nutritional program.

Clinical Study Results

In Long-Term Efficacy of the Elipse Gastric Balloon System: An International Multicenter Study, Dr Roberta Ienca and colleagues report on 509 patients who received the Elipse Balloon and were followed for 1 year. After 4 months of Elipse Balloon treatment patients achieved weight loss of 14.4 ยฑ 7.7kg or 13.9 ยฑ 6.4% of total body weight. At 1-year follow-up, 95% of this weight loss was sustained.

In Sequential Elipse Balloon Treatment: 1-Year Weight Loss Results Approximates Bariatric Surgery Results, Dr Roberta Ienca and colleagues report on 42 patients treated with sequential Elipse Balloons. Between 1 and 5 months following the passing of the first Elipse Balloon, a second balloon was placed.

After 4 months, mean weight loss and percent total body weight loss were 14.7 ยฑ 4.4kg and 14.4 ยฑ 3.6%, respectively. The second balloon resulted in an additional 8.8 ยฑ 5.7kg and 10.0 ยฑ 6.5% weight loss, respectively. In total, sequential balloon treatment resulted in weight loss of 22.0 +/- 9.0kg or 22.8 +/- 8.8%, and a body mass index (BMI) decrease of 8.1kg/m 2 from baseline.

โ€œBoth of these studies demonstrate the potential that the Allurion Program has in providing consumers with long-term and sustainable results.

โ€œAdditionally, this data indicates that consumers can achieve life-changing results without needing to undergo surgery, endoscopy or anesthesia.โ€

— Dr Shantanu Gaur, co-founder and CEO of Allurion

โ€œThe clinical data presented at Obesity Week is reflective of the increasing demand for our product around the world.

โ€œWe have tripled the number of patients treated in the past year and have created a reputation for clinical results that providers and patients can trust.โ€

— Benoit Chardon, Executive Vice President Commercial for Allurion

[Source(s): Allurion Technologies, Business Wire]


Related Content:
FDA Warns of Overinflation, Acute Pancreatitis with Certain Intragastric Balloons for Weight Loss
Allurion Files for PMA Submission of Elipse Gastric Balloon